Mir and Heinzerling have reported that some cases with PD-1/PD-L1 inhibitor immunotherapy-related heart failure, cardiomyopathy, myocarditis, and myocardial fibrosis may manifest normal troponin levels (Heinzerling et al., 2016; Mir et al., 2018). Here, PDCD1 is linked to cardiomyopathy.